多西紫杉醇联合顺铂在人骨肉瘤化疗中的作用Proliferation inhibition effect of docetaxel combined with cisplatin during the course of chemotherapy for osteosarcoma
陶海;蔡林;
摘要(Abstract)：
[目的]研究多西紫杉醇联合顺铂对人骨肉瘤细胞的增殖抑制及在骨肉瘤化疗中的作用。[方法]应用细胞计数、形态学观察、流式细胞术等方法检测和观察分别及联合应用多西紫杉醇和顺铂对人骨肉瘤细胞株的增殖抑制;建立裸鼠荷人骨肉瘤动物模型,分别及联合应用多西紫杉醇和顺铂对其进行治疗,并设立空白对照。观察瘤体的生长及病理指标。[结果]多西紫杉醇和顺铂分别及联合用药,在一定范围内均对骨肉瘤细胞有明显的增殖抑制和诱导凋亡作用,并且联合用药组作用明显强于单独用药组,抑制率≥59.34%(P<0.05;),凋亡率18.31%(P<0.01)。多西紫杉醇和顺铂单独应用均可抑制骨肉瘤瘤体的生长,肿瘤抑制指数分别为84.16%、78.53%;两者联合应用时作用更为明显,肿瘤抑制指数为96.78%。[结论]多西紫杉醇和顺铂联合用药比单独用药对骨肉瘤细胞株增殖抑制作用更强,在骨肉瘤化疗中的作用更强。
关键词(KeyWords)： 多西紫杉醇;骨肉瘤;裸鼠;凋亡
基金项目(Foundation): 湖北省科技攻关计划基金资助课题(NO.2004AA304B08)
作者(Author): 陶海;蔡林;
Email:
DOI:
参考文献(References)：
- [1]Gandara DR,Vokes E,Green M,et al.Activily of docetaxel inplatinumtreated non-small cell lung cancer:results of aphaseⅡmulticenter tri-al[J].Clin Oncol,2000,18:131-135.
- [2]Roth AD,Maibach R,Martinelli G,et al.Docetaxel(taxotere)-cisplatin(TC):an effeclive drug combination in gastric carcinoma:Swiss groupfor clinical cancer research(SAKK),and the european in statule of on-cology[J].Ann Oncol,2000,11:301-306.
- [3]Fabbri F,Carloni S,Brigliadori G,et al.Sequential events of apoptosisinvolving docetaxel,a microtubule-inferfering agent:a cytometric study[J].BMC Cell Biol,2006,7:6.
- [4]Mintz MB,Sowers R,Brown KM,et al.An expression signature classi-fies chemotherapy-resistant pediatric osteosarcoma[J].Cancer Res,2005,65(5):1748-1754.
- [5]Gunlinas-Lichius O,Appenrodt S,Veelken F,et al.PhaseⅡstudy ofweekly docetaxel and cisplatin in patients with advanced recurrent andmetastatic head and neck cancer[J].Laryngoscope,2006,116(4):613-618.
- [6]Lynch TJr,Kim E.Optimizing chemotherapy and targeted agenl com-binations in NSCLC[J].Lung Cancer,2005,50(Suppl 2):25-32.
- [7]Hironaka S,Zenda S,Boku N,et al.Weekly pacLitaxel as second-linechemotherapy for advanced or recurrent gastric cancer[J].GastricCancer,2006,9(1):14-18.
- [8]Tanaka T,Bat T,Yukawa K,et al.Optimal combination chemotherapyand chemoradiotherapy with etoposide for advanced cervical squamouscancer cells in vitro[J].Oncol Rep,2006,15(4):939-847.
- [9]Yan XJ,Liang LZ,Zeng ZY,et al.Effect of survivin shRNAon chemo-sensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel[J].Ai Zheng,2006,25(4):398-403.
- [10]Ricci MS,Zong WX.Chemotherapeutic approaches for targeting celldeath pathways[J].Oncologist,2006,11(4):342-357.